These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1856404)

  • 1. Clinical, physiologic, anatomic and procedural factors predictive of restenosis after percutaneous transluminal coronary angioplasty.
    Bourassa MG; Lespérance J; Eastwood C; Schwartz L; Côté G; Kazim F; Hudon G
    J Am Coll Cardiol; 1991 Aug; 18(2):368-76. PubMed ID: 1856404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group.
    Faxon DP
    J Am Coll Cardiol; 1995 Feb; 25(2):362-9. PubMed ID: 7829789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of restenosis after successful coronary angioplasty: improved clinical decision making with use of a logistic model combining procedural and follow-up variables.
    Renkin J; Melin J; Robert A; Richelle F; Bachy JL; Col J; Detry JM; Wijns W
    J Am Coll Cardiol; 1990 Nov; 16(6):1333-40. PubMed ID: 2229783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions--further evidence for the restenosis paradox. MERCATOR Study Group (Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis).
    Hermans WR; Foley DP; Rensing BJ; Serruys PW
    Am Heart J; 1994 Mar; 127(3):483-94. PubMed ID: 8122593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Verapamil treatment after coronary angioplasty in patients at high risk of recurrent stenosis.
    Hoberg E; Dietz R; Frees U; Katus HA; Rauch B; Schömig A; Schuler G; Schwarz F; Tillmanns H; Niebauer J
    Br Heart J; 1994 Mar; 71(3):254-60. PubMed ID: 8142195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
    Bertrand ME; McFadden EP; Fruchart JC; Van Belle E; Commeau P; Grollier G; Bassand JP; Machecourt J; Cassagnes J; Mossard JM; Vacheron A; Castaigne A; Danchin N; Lablanche JM
    J Am Coll Cardiol; 1997 Oct; 30(4):863-9. PubMed ID: 9316510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of diltiazem on complications and restenosis after coronary angioplasty.
    O'Keefe JH; Giorgi LV; Hartzler GO; Good TH; Ligon RW; Webb DL; McCallister BD
    Am J Cardiol; 1991 Feb; 67(5):373-6. PubMed ID: 1994661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restenosis after coronary angioplasty for rapidly progressive coronary stenosis.
    Bauters C; Passart F; Lablanche JM; McFadden EP; Hamon M; Bertrand ME
    Eur Heart J; 1996 Nov; 17(11):1671-7. PubMed ID: 8922915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
    Hermans WR; Rensing BJ; Foley DP; Tijssen JG; Rutsch W; Emanuelsson H; Danchin N; Wijns W; Chappuis F; Serruys PW
    J Cardiovasc Pharmacol; 1993; 22 Suppl 4():S45-57. PubMed ID: 7523772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.
    Schwartz L; Bourassa MG; Lespérance J; Aldridge HE; Kazim F; Salvatori VA; Henderson M; Bonan R; David PR
    N Engl J Med; 1988 Jun; 318(26):1714-9. PubMed ID: 2967433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of antiplatelet agents in modifying the extent of restenosis following percutaneous transluminal coronary angioplasty.
    Schwartz L; Lesperance J; Bourassa MG; Eastwood C; Kazim F; Arafah M; Ganassin L
    Am Heart J; 1990 Feb; 119(2 Pt 1):232-6. PubMed ID: 2405609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.
    Tsuchikane E; Fukuhara A; Kobayashi T; Kirino M; Yamasaki K; Kobayashi T; Izumi M; Otsuji S; Tateyama H; Sakurai M; Awata N
    Circulation; 1999 Jul; 100(1):21-6. PubMed ID: 10393676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restenosis after delayed coronary angioplasty of the culprit vessel in patients with a recent myocardial infarction treated by thrombolysis.
    Bauters C; Khanoyan P; McFadden EP; Quandalle P; Lablanche JM; Bertrand ME
    Circulation; 1995 Mar; 91(5):1410-8. PubMed ID: 7867181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can restenosis after coronary angioplasty be predicted from clinical variables?
    Weintraub WS; Kosinski AS; Brown CL; King SB
    J Am Coll Cardiol; 1993 Jan; 21(1):6-14. PubMed ID: 8417077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II).
    Savage MP; Goldberg S; Bove AA; Deutsch E; Vetrovec G; Macdonald RG; Bass T; Margolis JR; Whitworth HB; Taussig A
    Circulation; 1995 Dec; 92(11):3194-200. PubMed ID: 7586303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT).
    Serruys PW; Rutsch W; Heyndrickx GR; Danchin N; Mast EG; Wijns W; Rensing BJ; Vos J; Stibbe J
    Circulation; 1991 Oct; 84(4):1568-80. PubMed ID: 1833088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restenosis rate after multiple percutaneous transluminal coronary angioplasty procedures at the same site. A quantitative angiographic study in consecutive patients undergoing a third angioplasty procedure for a second restenosis.
    Bauters C; Mc Fadden EP; Lablanche JM; Quandalle P; Bertrand ME
    Circulation; 1993 Sep; 88(3):969-74. PubMed ID: 8353924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. The M-HEART Investigators.
    Hirshfeld JW; Schwartz JS; Jugo R; MacDonald RG; Goldberg S; Savage MP; Bass TA; Vetrovec G; Cowley M; Taussig AS
    J Am Coll Cardiol; 1991 Sep; 18(3):647-56. PubMed ID: 1869725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chlamydia pneumoniae seropositivity predicts the risk of restenosis after percutaneous transluminal coronary angioplasty.
    Hayashida K; Tanaka M; Morita H; Hayashi F; Inada T; Suzuki H; Sakamoto T; Katsuragawa M; Hibino H; Kambara H
    Heart Vessels; 2002 May; 16(4):137-45. PubMed ID: 12224784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic dissection after successful coronary balloon angioplasty: no influence on restenosis or on clinical outcome in 693 patients. The MERCATOR Study Group (Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis).
    Hermans WR; Rensing BJ; Foley DP; Deckers JW; Rutsch W; Emanuelsson H; Danchin N; Wijns W; Chappuis F; Serruys PW
    J Am Coll Cardiol; 1992 Oct; 20(4):767-80. PubMed ID: 1388181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.